Patent: Neuroprotection and myelin repair using Nestorone.RTM
Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17.alpha.-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.
Sitruk-Ware, Régine, Michael Schumacher, Maria Helmut, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, and Rachida Guennoun. Neuroprotection and myelin repair using Nestorone.RTM. US Patent 10,052,335, filed 2010, and issued 2018.
United States Patent 10,052,335